Open-label pilot study of interferon gamma-1b in Friedreich ataxia. L. Seyer, N. Greeley, D. Foerster, C. Strawser, S. Gelbard, Y. Dong, K. Schadt, M. G. Cotticelli, A. Brocht, J. Farmer, R. B. Wilson and D. R. Lynch; Acta Neurol Scand: DOI: 10.1111/ane.12337.
Conclusions – Interferon gamma-1b improved FARS scores without a clear relationship to changes in frataxin levels. Larger, longer placebo-controlled trials including biochemical assessments in affected tissues are necessary to evaluate fully the efficacy and utility of IFN-c in FRDA.
Wednesday, October 22, 2014
Subscribe to:
Posts (Atom)
